The latest market report published by Credence Research, Inc. “Global Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028. The global market for Non-alcoholic Steatohepatitis (Nash) Biomarkers has steadily risen in recent years and is predicted to increase at a CAGR of 23.10% between 2023 and 2030. The market was worth USD 0.91 billion in 2022 and is predicted to be around USD 3.91 billion by 2030.
Non-Alcoholic Steatohepatitis (NASH) has emerged as a significant health concern globally. NASH is a progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD), characterized by hepatic inflammation and injury that can lead to fibrosis, cirrhosis, and even hepatocellular carcinoma. Given the growing prevalence of NASH, the need for reliable and accurate biomarkers for its early diagnosis, prognosis, and monitoring has become paramount. In this article, we delve deep into the world of NASH biomarkers, exploring the current state of research, advancements, challenges, and potential breakthroughs.
Understanding NASH Biomarkers
NASH biomarkers are measurable substances in the body that indicate the presence, severity, or progression of NASH. These biomarkers can be in the form of proteins, lipids, enzymes, cytokines, or genetic markers. Accurate biomarkers play a crucial role in identifying patients at risk of developing NASH, facilitating timely intervention and personalized treatment plans.
Current Landscape of NASH Biomarker Research
The medical research community has been fervently investigating various potential NASH biomarkers to address the diagnostic and prognostic gaps. Liver biopsies have been the gold standard for NASH diagnosis, but they come with inherent risks and limitations. As a result, researchers have focused on non-invasive biomarkers that can provide reliable information without the need for invasive procedures.
State-of-the-Art Biomarkers for NASH
FibroTest: A composite biomarker panel that assesses the level of liver fibrosis, providing valuable insights into disease progression.
NAFLD Fibrosis Score: A non-invasive tool to evaluate the likelihood of advanced fibrosis in NAFLD and NASH patients.
Enhanced Liver Fibrosis (ELF) Test: An advanced blood test that measures key biomarkers associated with liver fibrosis.
Emerging Biomarkers with High Potential
miRNAs: MicroRNAs have shown promise as potential NASH biomarkers due to their regulatory roles in gene expression.
Oxidative Stress Markers: Biomarkers indicating oxidative stress in liver tissues may help in assessing disease severity.
Cytokeratin-18 (CK-18): An apoptotic biomarker that reflects hepatocyte death and has been studied for NASH prognosis.
Browse 200 pages report Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others) By End-use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes) – Growth, Future Prospects & Competitive Analysis, 2016 – 2030)- https://www.credenceresearch.com/report/non-alcoholic-steatohepatitis-nash-biomarkers-market
The NASH biomarkers market is poised for remarkable growth, driven by increasing awareness, research funding, and advancements in diagnostic technologies. As novel biomarkers continue to emerge, healthcare professionals will gain better tools to identify NASH earlier, enabling timely interventions and improved patient outcomes.
Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Dynamics refer to the ever-evolving landscape of diagnostic tools and techniques aimed at identifying and monitoring NASH, a progressive form of liver disease characterized by inflammation and fatty deposits in the liver tissue. These biomarkers play a crucial role in understanding the disease’s pathogenesis, predicting its progression, assessing treatment efficacy, and facilitating drug development. The market dynamics of NASH biomarkers are driven by various factors such as increasing prevalence of obesity-related diseases, rising awareness about NASH among healthcare professionals and patients, advancements in laboratory technologies for accurate diagnosis, and growing demand for non-invasive testing methods.
Why to Buy This Report-
- The report provides a qualitative as well as quantitative analysis of the global Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
- The report includes information on the competitive landscape, such as how the market’s top competitors operate at the global, regional, and country levels.
- Major nations in each region with their import/export statistics
- The global Non-Alcoholic Steatohepatitis (Nash) Biomarkers Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.
About Us –
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.
Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India